The Bilgicer Group focuses on both understanding the basic dynamic principles of multivalent biomolecular interactions, as well as design of multivalent therapeutic and diagnostic molecules which will deliver novel solutions to complex diseases (e.g. cancer, autoimmune diseases, and allergies.)
Research Areas:
News
View all news
Media Mentions
More mentionsNovel allergen inhibitor successfully prevents peanut reaction in mice
April 19, 2023
As Başar Bilgiçer co-author of the study explained, the reality is that “in the case of peanut allergy, there is no pathogen, just peanut proteins.”
Peanut allergy drug staves off anaphylaxis for 2 weeks with a single dose
February 13, 2023
“These new findings suggest that cHBI has the potential to be an effective preventative for peanut-specific allergic responses in patients,” said co-senior author Basar Bilgicer, Ph.D.
WSBT TV
Severe peanut allergy breakthrough by Indiana University and Notre Dame researchers
February 10, 2023
Professor Basar Bilgicer and his students have been hard at work on this project. It's one he's been invested in since 2008 and it's not a program that could've been rushed.
Originally published at news.nd.edu.